Irinotecanhydrochlorid 3 H2o Bhardwaj (Irinotecan)

Irinotecan is a prodrug that is converted inside cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, preventing the re‑ligation of single‑strand DNA breaks. This leads to accumulation of DNA damage, inhibition of DNA replication, and ultimately death of rapidly dividing cancer cells.

The dose of Irinotecanhydrochlorid is individualized by the prescribing oncologist based on factors such as body surface area, type of tumor, previous therapy, and patient tolerance. No fixed regimen is provided here; the prescriber determines the appropriate amount and schedule for each patient.

Irinotecan is classified as Pregnancy Category D, indicating evidence of fetal risk, and it is not recommended for use during pregnancy. Breastfeeding is also contraindicated because the drug is excreted in milk and may harm a nursing infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, oncology centres, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from topoisomerase II inhibitors such as etoposide. Compared with agents like topotecan, irinotecan generally has a broader indication spectrum, especially for colorectal cancer, and its toxicity profile includes prominent diarrhea and neutropenia. Choice of therapy depends on tumor type, prior treatment, and patient-specific factors.

The product should be stored at 2‑8 °C in a refrigerator, protected from light. It must not be frozen or shaken. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic techniques during preparation and administration.

Irinotecanhydrochlorid is given as an intravenous infusion, typically over 30 to 90 minutes depending on the regimen and patient tolerance. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring of vital signs and laboratory parameters before, during, and after administration.

The most serious risks include severe neutropenia leading to infection, febrile neutropenia, and life‑threatening diarrhea or colitis that may progress to intestinal perforation. Prompt recognition and supportive care are essential. Patients should be educated to report fever, persistent diarrhea, or signs of infection immediately.

Irinotecanhydrochlorid is contraindicated in patients with known hypersensitivity to irinotecan or any component of the formulation, those with severe bone‑marrow suppression, uncontrolled infections, and pregnant women. Caution is also advised for patients with significant hepatic impairment or pre‑existing gastrointestinal disorders.